27. Aug 2026
Description
(AWP Alliance News) - MindMaze Therapeutics posted a net loss of CHF 6.93 million for the six months ended June 30, 2026, widening from CHF 3.29 million a year earlier as total revenue rose to CHF 586,000 from CHF 32,000. Operating loss deepened to CHF 6.71 million from CHF 5.15 million, while basic and diluted loss per share narrowed to CHF 0.045 from CHF 0.262. Cash and cash equivalents fell to CHF 5.32 million at June 30 from CHF 9.47 million at the end of 2025, while net cash used in operating activities increased to CHF 8.73 million from CHF 2.43 million. CEO Zach Henderson said the group has simplified operations around neurotherapeutics following the Relief Therapeutics merger, citing a growing U.S. sales pipeline and a planned initial launch phase for its pharmaceutical distribution collaboration in the fourth quarter of 2026.
https://docs.publicnow.com/BF813BF4BABB04B55682417F848D6AAE8A3F6542
Disclaimer: This news brief was created using generative artificial intelligence. MindMaze Therapeutics Holding SA published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.
